Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 4 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-63M | $-58M | $-54M | -54.0% | - | 179.7% |
| 2024 | $0M | $-23M | $-21M | $-18M | 37.7% | - | 185.6% |
| 2023 | $0M | $-7M | $-7M | $-6M | 20.7% | - | -46.9% |
| 2022 | $0M | $-11M | $-14M | $-11M | 48.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Operating Expense | 62.72 |
| Research And Development | 48.94 |
| Selling General And Administration | 13.79 |
| Total Expenses | 62.72 |
| Operating Income | -62.72 |
| Total Operating Income As Reported | -62.72 |
| EBITDA | -62.69 |
| Normalized EBITDA | -62.68 |
| EBIT | -62.72 |
| Interest Income | 5.14 |
| Net Interest Income | 5.14 |
| Other Income Expense | 0 |
| Interest Income Non Operating | 5.14 |
| Net Non Operating Interest Income Expense | 5.14 |
| Pretax Income | -57.59 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -57.59 |
| Net Income From Continuing And Discontinued Operation | -57.59 |
| Net Income From Continuing Operation Net Minority Interest | -57.59 |
| Net Income | -57.59 |
| Net Income Common Stockholders | -57.59 |
| Net Income Including Noncontrolling Interests | -57.59 |
| Normalized Income | -57.59 |
| Diluted NI Availto Com Stockholders | -57.59 |
| Basic Average Shares | 19.62 |
| Diluted Average Shares | 19.62 |
| Reconciled Depreciation | 0.04 |
| Total Unusual Items | 0 |
| Total Unusual Items Excluding Goodwill | 0 |
| Special Income Charges | 0 |
| Other Special Charges | - |
| Write Off | 0 |
| Gain On Sale Of Security | 0 |
| General And Administrative Expense | 13.79 |
| Other Gand A | 13.79 |
| Provision For Doubtful Accounts | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc.this co. | AARD | $86M | -1.49 | 0.81 | -54.0% | -0.63 |
| Neuronetics, Inc. | STIM | $102M | -2.61 | 4.54 | -174.3% | -5.84 |
| OptimizeRx Corporation | OPRX | $101M | 19.67 | 0.79 | 4.0% | 6.26 |
| Definitive Healthcare Corp. | DH | $96M | -0.69 | 0.34 | -49.4% | -0.74 |
| Heron Therapeutics, Inc. | HRTX |
| $92M |
| - |
| 6.39 |
| -141.0% |
| - |
| Outset Medical, Inc. | OM | $88M | -1.07 | 0.69 | -64.3% | -2.46 |
| biote Corp. | BTMD | $84M | 3.10 | -1.43 | -46.2% | 3.25 |
| Pulmonx Corporation | LUNG | $68M | - | 1.26 | -99.8% | - |
| LENSAR, Inc. | LNSR | $68M | -1.98 | -2.61 | 131.7% | -2.88 |
| Peer Median | - | -0.88 | 0.74 | -56.9% | -1.60 | |